|
Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.sz) Avaliação DCF
CN | Healthcare | Drug Manufacturers - Specialty & Generic | SHZ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) Bundle
Explore o futuro financeiro do Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424SZ) com a nossa calculadora DCF fácil de usar! Digite suas suposições de crescimento, margens e custos para determinar o valor intrínseco do Grupo de Bailing Guizhou Pharmaceutical Co., Ltd. (002424SZ) e informe sua estratégia de investimento.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,850.6 | 3,087.9 | 3,111.6 | 3,540.1 | 4,263.0 | 4,724.3 | 5,235.5 | 5,802.0 | 6,429.8 | 7,125.5 |
| Revenue Growth, % | 0 | 8.32 | 0.7695 | 13.77 | 20.42 | 10.82 | 10.82 | 10.82 | 10.82 | 10.82 |
| EBITDA | 548.4 | 412.7 | 353.4 | 370.0 | -298.6 | 447.9 | 496.4 | 550.1 | 609.7 | 675.6 |
| EBITDA, % | 19.24 | 13.37 | 11.36 | 10.45 | -7 | 9.48 | 9.48 | 9.48 | 9.48 | 9.48 |
| Depreciation | 97.8 | 117.0 | 113.8 | 123.5 | 116.7 | 161.6 | 179.1 | 198.5 | 219.9 | 243.7 |
| Depreciation, % | 3.43 | 3.79 | 3.66 | 3.49 | 2.74 | 3.42 | 3.42 | 3.42 | 3.42 | 3.42 |
| EBIT | 450.6 | 295.7 | 239.6 | 246.6 | -415.3 | 286.3 | 317.3 | 351.7 | 389.7 | 431.9 |
| EBIT, % | 15.81 | 9.57 | 7.7 | 6.96 | -9.74 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 |
| Total Cash | 1,136.9 | 1,031.0 | 465.6 | 605.0 | 417.9 | 1,087.8 | 1,205.5 | 1,335.9 | 1,480.5 | 1,640.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2,196.6 | 2,659.8 | 1,980.7 | 2,207.3 | 2,364.0 | 3,256.5 | 3,608.9 | 3,999.4 | 4,432.1 | 4,911.7 |
| Account Receivables, % | 77.06 | 86.14 | 63.65 | 62.35 | 55.46 | 68.93 | 68.93 | 68.93 | 68.93 | 68.93 |
| Inventories | 1,006.9 | 783.5 | 844.8 | 804.8 | 1,163.7 | 1,302.8 | 1,443.7 | 1,600.0 | 1,773.1 | 1,964.9 |
| Inventories, % | 35.32 | 25.37 | 27.15 | 22.73 | 27.3 | 27.58 | 27.58 | 27.58 | 27.58 | 27.58 |
| Accounts Payable | 161.9 | 558.4 | 403.9 | 581.3 | 904.8 | 702.8 | 778.9 | 863.2 | 956.6 | 1,060.1 |
| Accounts Payable, % | 5.68 | 18.08 | 12.98 | 16.42 | 21.22 | 14.88 | 14.88 | 14.88 | 14.88 | 14.88 |
| Capital Expenditure | -121.9 | -90.0 | -425.7 | -68.5 | -104.1 | -238.6 | -264.4 | -293.0 | -324.7 | -359.8 |
| Capital Expenditure, % | -4.28 | -2.92 | -13.68 | -1.93 | -2.44 | -5.05 | -5.05 | -5.05 | -5.05 | -5.05 |
| Tax Rate, % | 15.93 | 15.93 | 15.93 | 15.93 | 15.93 | 15.93 | 15.93 | 15.93 | 15.93 | 15.93 |
| EBITAT | 358.1 | 215.8 | 192.2 | 214.7 | -349.1 | 231.2 | 256.3 | 284.0 | 314.7 | 348.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -2,707.7 | 399.5 | 343.6 | 260.4 | -528.7 | -1,079.2 | -246.3 | -273.0 | -302.5 | -335.3 |
| WACC, % | 5.93 | 5.85 | 5.94 | 6.02 | 5.99 | 5.95 | 5.95 | 5.95 | 5.95 | 5.95 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,959.0 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | -349 | |||||||||
| Terminal Value | -17,924 | |||||||||
| Present Terminal Value | -13,428 | |||||||||
| Enterprise Value | -15,387 | |||||||||
| Net Debt | 1,257 | |||||||||
| Equity Value | -16,645 | |||||||||
| Diluted Shares Outstanding, MM | 1,382 | |||||||||
| Equity Value Per Share | -12.05 |
What You Will Receive
- Authentic 002424SZ Financial Data: Pre-filled with Guizhou Bailing Group Pharmaceutical’s historical and forecasted data for accurate analysis.
- Completely Customizable Template: Easily adjust key parameters such as revenue growth, WACC, and EBITDA percentage.
- Instantaneous Calculations: Watch the intrinsic value of Guizhou Bailing Group update in real-time as you modify inputs.
- Expert Valuation Tool: Tailored for investors, analysts, and consultants in need of precise DCF outputs.
- Intuitive Interface: Designed with a straightforward layout and clear guidance to accommodate all skill levels.
Key Features
- 🔍 Real-Life Bailing Group Financials: Pre-filled historical and projected data for Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424SZ).
- ✏️ Fully Customizable Inputs: Modify all essential parameters (yellow cells) including WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Integrated formulas compute the intrinsic value of Guizhou Bailing Group using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize the valuation for Guizhou Bailing Group instantly upon making adjustments.
- Scenario Analysis: Explore and compare outcomes for different financial scenarios side-by-side.
How It Functions
- Step 1: Download the Excel spreadsheet.
- Step 2: Examine the pre-filled data for Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424SZ) (historical and forecasted).
- Step 3: Modify the key assumptions (highlighted in yellow) according to your analysis.
- Step 4: Observe automatic updates for the intrinsic value of Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424SZ).
- Step 5: Utilize the results for investment strategies or reporting purposes.
Why Select This Calculator for Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424SZ)?
- User-Friendly Interface: Tailored for both newcomers and seasoned professionals.
- Customizable Inputs: Adjust variables easily to suit your specific analysis needs.
- Real-Time Feedback: Instantly observe changes in Guizhou Bailing’s valuation as you modify inputs.
- Pre-Loaded Data: Comes with Guizhou Bailing’s actual financial figures for swift analysis.
- Endorsed by Experts: Favored by investors and analysts for making well-informed decisions.
Who Can Benefit from Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424SZ)?
- Investors: Make informed investment choices with our comprehensive valuation insights.
- Financial Analysts: Streamline your workflow with customizable financial models tailored for the pharmaceutical industry.
- Consultants: Effortlessly modify templates for tailored client presentations and comprehensive reports.
- Pharmaceutical Enthusiasts: Enhance your knowledge of valuation methodologies through practical, real-world applications.
- Educators and Students: Utilize our resources as a hands-on tool for finance and pharmaceutical courses.
Contents of the Template
- Pre-Filled DCF Model: Guizhou Bailing Group Pharmaceutical’s financial data ready for immediate application.
- WACC Calculator: Comprehensive calculations for Weighted Average Cost of Capital.
- Financial Ratios: Assess Guizhou Bailing Group's profitability, leverage, and efficiency metrics.
- Editable Inputs: Modify assumptions like growth rates, margins, and CAPEX to align with your scenarios.
- Financial Statements: Annual and quarterly reports to facilitate in-depth analysis.
- Interactive Dashboard: Effortlessly visualize essential valuation metrics and outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.